» Articles » PMID: 33512757

Quantitative Vibration Perception Threshold in Assessing Diabetic Polyneuropathy: Should the Cut-off Value Be Adjusted for Chinese Individuals with Type 2 Diabetes?

Overview
Specialty Endocrinology
Date 2021 Jan 29
PMID 33512757
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/introduction: To examine the performance and identify the optimal threshold of vibration perception threshold (VPT) for diagnosing diabetic polyneuropathy (DPN) in a Chinese population according to multiple definitions of DPN as gold standards.

Materials And Methods: VPT was determined in 421 Chinese individuals with type 2 diabetes, who simultaneously completed a questionnaire of neuropathic symptoms, and underwent the assessment of signs of peripheral neuropathy and electromyography tests. Three definitions of DPN (i.e., clinician-diagnosed DPN, abnormal nerve conduction and confirmed DPN) were taken as reference gold standards.

Results: Vibration perception threshold was a specific measure for all three groups of DPN outcomes, with the highest specificity noted for clinician-diagnosed DPN (85.1%). The specificity for abnormal nerve conduction and confirmed DPN was 77.0 and 76.6%, respectively. The sensitivity of VPT was 67.0% for clinician-diagnosed DPN, 66.5% for abnormal nerve conduction and 67.2% for confirmed DPN. The optimal cut-off threshold for abnormal nerve conduction, as well as confirmed DPN, was VPT >14.9 V. The specificity and sensitivity of VPT >14.9 V as the cut-off value for clinician-diagnosed DPN were 85.6 and 66.2%, respectively. When taking clinician-diagnosed DPN as the gold standard, the performance of VPT for diagnosing DPN was best with an area under the curve value of 0.804.

Conclusions: VPT measured using the neurothesiometer had relatively high specificity and best performance for diagnosing DPN when clinician-diagnosed DPN rather than abnormal nerve conduction was taken as the gold standard in a Chinese population. A VPT value of ≥15 V might be equally applicable for diagnosing DPN in a Chinese population.

Citing Articles

Foot screening and customized health education program for patients with diabetic peripheral neuropathy: A nurse-led, real-world observational study.

Liu S, Ding H, Li D, Lu F, Luo G, He Y Int J Nurs Stud Adv. 2025; 8:100291.

PMID: 39896918 PMC: 11787437. DOI: 10.1016/j.ijnsa.2025.100291.


Causality between sarcopenia and diabetic neuropathy.

Fang Y, Yuan X, Zhang Q, Liu J, Yao Q, Ye X Front Endocrinol (Lausanne). 2024; 15:1428835.

PMID: 39345878 PMC: 11427279. DOI: 10.3389/fendo.2024.1428835.


Association of high vibration perception threshold with reduced renal function in patients with type 2 diabetes.

Zhang Y, Zheng B, Li Y, Shen X, Huang L, Zhao F Front Endocrinol (Lausanne). 2024; 15:1357294.

PMID: 38872969 PMC: 11169863. DOI: 10.3389/fendo.2024.1357294.


Can the 128-Hz tuning fork be an alternative to the biothesiometer for diabetic peripheral neuropathy screening? A cross-sectional study in a tertiary hospital in East India.

Chattopadhyay S, Goswami S, Sengupta N, Baidya A BMJ Open. 2024; 14(6):e082193.

PMID: 38862223 PMC: 11168183. DOI: 10.1136/bmjopen-2023-082193.


Early detection of diabetic neuropathy based on health belief model: a scoping review.

Purwanti O, Nursalam N, Pandin M Front Endocrinol (Lausanne). 2024; 15:1369699.

PMID: 38721145 PMC: 11076868. DOI: 10.3389/fendo.2024.1369699.


References
1.
Tesfaye S, Stevens L, Stephenson J, Fuller J, Plater M, Ionescu-Tirgoviste C . Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996; 39(11):1377-84. DOI: 10.1007/s001250050586. View

2.
Santos T, Melo J, Leite N, Salles G, Lopes Cardoso C . Usefulness of the vibration perception thresholds measurement as a diagnostic method for diabetic peripheral neuropathy: Results from the Rio de Janeiro type 2 diabetes cohort study. J Diabetes Complications. 2018; 32(8):770-776. DOI: 10.1016/j.jdiacomp.2018.05.010. View

3.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

4.
Martin C, Waberski B, Pop-Busui R, Cleary P, Catton S, Albers J . Vibration perception threshold as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the DCCT/EDIC study. Diabetes Care. 2010; 33(12):2635-41. PMC: 2992204. DOI: 10.2337/dc10-0616. View

5.
Tesfaye S, Chaturvedi N, Eaton S, Ward J, Manes C, Ionescu-Tirgoviste C . Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005; 352(4):341-50. DOI: 10.1056/NEJMoa032782. View